# CJC-1295 Buy — Frequently asked questions on legality, supply, vendors, and the WADA listing

> Editorial answers to the questions that recur in search around buying CJC-1295: U.S. legal status, why compounding pharmacy supply is restricted, DAC vs non-DAC, vendor verification, anti-doping consequences, and what the published research actually shows.

The questions below are the ones the search data shows readers asking about buying CJC-1295. The answers are editorial — what the literature, the FDA briefings, and the WADA standards say. They are not legal, medical, or purchasing advice.

## Is it legal to buy CJC-1295 in the United States?

CJC-1295 is not a scheduled controlled substance under the U.S. Controlled Substances Act. It is also not an FDA-approved drug for any human indication. Those two facts together place it in a regulatory gray area that varies by transaction.

The FDA placed CJC-1295 in Section 503A Category 2 in 2023 — substances not approved for routine pharmacy compounding pending FDA review [13]. At the October 2024 Pharmacy Compounding Advisory Committee meeting, members reviewed evidence on five chemical forms of the compound and did not recommend inclusion on the 503A bulk drug substances list; a December 2024 follow-up briefing reiterated insufficient evidence [13, 17]. The practical effect is that traditional U.S. compounding pharmacies cannot lawfully prepare CJC-1295 for individual patient prescriptions under 503A.

The compound continues to appear in distribution channels labeled 'research chemical' — a designation that the suppliers themselves apply to indicate the product is not approved for human use and is sold for in vitro or non-human laboratory investigation only. The legality of any specific transaction depends on jurisdiction, on the seller's regulatory standing, on the buyer's stated purpose, and on whether the transaction crosses borders. This site does not provide legal advice and does not direct readers to vendors.

## Why has U.S. compounding pharmacy supply been restricted?

Section 503A of the Federal Food, Drug, and Cosmetic Act allows traditional pharmacies to compound drug products for individual patient prescriptions. The bulk drug substances that may be used in 503A compounding are governed by FDA review and listing. CJC-1295 was placed in 503A Category 2 in 2023 — substances under FDA review and not approved for routine 503A compounding access.

The FDA Pharmacy Compounding Advisory Committee took up CJC-1295 at its October 29, 2024 meeting. According to the public briefing materials, members considered the available pharmacology, safety, and historical-use evidence for five chemical forms across the DAC and non-DAC variants and did not recommend inclusion on the 503A bulks list [13]. A December 4, 2024 follow-up briefing on the broader GH-secretagogue peptide class consolidated public comment, manufacturer evidence submissions, and adverse-event signal review and reiterated insufficient evidence to support routine 503A access for the class [17]. CJC-1295 therefore remains in Category 2.

## What is the difference between CJC-1295 DAC and 'CJC-1295 without DAC'?

Two distinct compounds are routinely sold under the 'CJC-1295' label. The pharmacokinetic difference between them is roughly two orders of magnitude in plasma persistence.

CJC-1295 with DAC — the original ConjuChem compound — is the 30-amino-acid GHRH analog with a C-terminal maleimidopropionic acid group that covalently binds to the free thiol on Cys34 of serum albumin after subcutaneous injection [1]. The mean plasma half-life of the resulting bioconjugate in healthy adults is between 5.8 and 8.1 days [3].

CJC-1295 without DAC — also called modified GRF (1-29) or mod GRF 1-29 — is the same 29-amino-acid backbone with the four protective substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) but without the maleimide-albumin bond. Its plasma half-life is approximately 30 minutes [8].

The two compounds were sometimes used in different research designs for different reasons. Vendors and discussion forums frequently conflate them. They are not interchangeable from a pharmacokinetic standpoint.

## Why is CJC-1295 commonly sold paired with ipamorelin?

The 'CJC-1295 + ipamorelin' pairing has a documented mechanistic basis. CJC-1295 binds the GHRH receptor. Ipamorelin binds GHS-R1a, the ghrelin receptor. The two receptors converge on growth hormone release through distinct signaling pathways, and combined activation produces a GH secretory response several-fold larger than either agent alone [15].

The foundational study demonstrating this dual-receptor synergy was Bowers and colleagues in 1990, who administered native GHRH and the ghrelin-receptor agonist GHRP-6 to healthy adults [15]. The CJC-1295 + ipamorelin pairing extends that mechanism to longer-acting analogs and is the most commonly co-listed peptide blend in research-chemical supplier catalogs.

No controlled human efficacy or safety studies of the CJC-1295 + ipamorelin combination at the doses or schedules sold in research-chemical channels have been published.

## How can a buyer verify the identity of CJC-1295 from a vendor?

The peer-reviewed analytical literature establishes that the only definitive identification of CJC-1295 in a finished pharmaceutical preparation is by sequence-level mass spectrometric analysis. In 2010, Henninge and colleagues used liquid chromatography high-resolution tandem mass spectrometry to identify CJC-1295 in an unknown pharmaceutical preparation seized through enforcement channels [9]. In 2024, Thomas and colleagues published validated nano-LC Orbitrap mass spectrometry methods for routine detection of CJC-1295 and related GHRH analogs in athlete urine [11].

In practical terms: paper certificates of analysis provided by vendors are documents about a batch, not the specific vial in a buyer's hand. The literature documents that the identity, purity, and sterility of peptides in non-pharmaceutical channels are not assured — the seized-material analysis was published precisely because what was on the label and what was in the preparation could not otherwise be confirmed [9]. A buyer who needs to confirm identity has to submit a sample to a qualified analytical laboratory.

## What are the documented risks of acquiring CJC-1295 from unregulated vendors?

The published literature documents three categories of concern.

First, identity: an unknown pharmaceutical preparation seized through enforcement channels was confirmed to contain CJC-1295 only after sequence-level mass spectrometric analysis [9]. The implication — that the contents of unregulated preparations cannot be confirmed from labeling alone — is general to the gray-market peptide channel.

Second, purity and sterility: peptide products distributed through research-chemical channels are not subject to pharmacopoeial standards for impurity profiles, residual solvents, endotoxin content, or sterility. The 2024 FDA Pharmacy Compounding Advisory Committee briefings explicitly cited absence of quality-controlled supply as part of the safety evaluation for the GH-secretagogue peptide class [13, 17].

Third, the documented behavioral pattern: a 2016 netnographic analysis of nine online bodybuilding forums documented user-reported safety anxieties around product purity and around the absence of clinical oversight when acquiring CJC-1295 through non-clinical channels [10]. The published clinical literature does not address long-term consequences of unsupervised use because no controlled studies of those use patterns exist.

## Is CJC-1295 a prescription drug?

CJC-1295 is not an FDA-approved drug for any human indication. It therefore has no FDA-approved labeled use under which a U.S. clinician could prescribe it on-label. It is also not a scheduled controlled substance under the Controlled Substances Act.

Prior to the 2023 503A Category 2 designation, the compound was reportedly available through some compounding pharmacies for individual patient prescriptions; the FDA's Category 2 placement and the 2024 PCAC committee declining to add the compound to the 503A bulks list have restricted that channel [13, 17]. The compound continues to appear in distribution channels labeled 'research chemical' that explicitly exclude human-use claims.

## Does buying CJC-1295 have anti-doping consequences?

For any athlete subject to the World Anti-Doping Code, the consequences are direct. CJC-1295 is listed on the 2025 WADA Prohibited List under Section S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — at all times, both in-competition and out-of-competition [16]. Article 2.6 of the WADA Code establishes that possession of a prohibited substance by an athlete or athlete support personnel is sufficient for an Anti-Doping Rule Violation.

Detection is no longer the analytical challenge it once was. The Thomas 2024 methodology paper documents validated nano-LC Orbitrap mass spectrometry methods for routine detection of CJC-1295 in urine at sub-nanogram-per-milliliter limits, meeting WADA technical requirements [11].

For individuals not subject to the WADA Code, there is no anti-doping consequence by definition. Other consequences — employer testing policies, insurance, professional licensing — are jurisdiction- and context-specific and are outside the scope of this dossier.

## What does the published clinical literature actually show?

The published human evidence base is narrow. A single Phase 1 dose-ranging study in healthy adults established that subcutaneous CJC-1295 produces sustained mean GH and IGF-1 elevation lasting days after single doses, with a mean plasma half-life of 5.8 to 8.1 days [2, 3]. A companion paper established that pulsatile GH secretion is preserved during continuous CJC-1295 stimulation [6]. A proteomic study identified candidate serum biomarkers of GH/IGF-1 axis activation downstream of CJC-1295 administration [5].

The only Phase 2 trial — NCT00267527, in HIV-associated visceral adiposity — was terminated in October 2006 after a participant died of an acute coronary event that an independent review judged unrelated to study drug. The trial did not restart, and primary efficacy endpoints were never published [7].

There are no published long-term human efficacy or safety randomized controlled trials of CJC-1295.

## Why does this site exist if it doesn't sell CJC-1295?

Because the search query 'CJC-1295 buy' is dominated by vendor product listings, and the regulatory, clinical, and analytical record of the compound is genuinely informative public-interest material that is harder to find than a vendor catalog. This site is an editorial dossier that catalogs what the peer-reviewed and regulatory record says. It does not sell CJC-1295, does not facilitate its purchase, does not link to vendors, and is not affiliated with any pharmacy, compounder, research-chemical supplier, or clinic. The 'buy' in the domain name is a marker of the search intent the page addresses editorially, not a description of services the site offers.

## What labeling and documentation accompany legitimately-supplied research peptide?

Material distributed under the 'research chemical' designation is conventionally labeled for research use only and accompanied by some form of certificate of analysis describing identity, purity by HPLC or mass spectrometry, and sometimes residual solvent and endotoxin testing. A certificate of analysis is a document about a batch, prepared by or for the supplier, not an independent verification of the specific vial in a buyer's possession [9].

For research peptide acquired by a legitimately funded laboratory operating under institutional oversight, the more durable documentation chain runs through purchase orders, accession records, freezer logs, and — where the research design requires it — confirmatory analytical work performed independently of the supplier. None of that is purchasing advice; it is a description of how published research-grade peptide is conventionally documented in academic and contract-research settings.

## Was the 2006 Phase 2 death caused by CJC-1295?

The independent safety review of the NCT00267527 trial attributed the participant's acute coronary event to pre-existing undiagnosed coronary artery disease and judged it unrelated to study drug [7]. The trial was nonetheless terminated and was not restarted, and ConjuChem Biotechnologies did not pursue further clinical development of CJC-1295. Primary efficacy endpoints from the trial were never published.

The formal regulatory record therefore reads: a participant death adjudicated as unrelated to study drug, in the only Phase 2 trial of the compound, after which sponsor-funded clinical development ceased. The published peer-reviewed literature does not contain a contradictory finding.

---

An independent editorial record of what the published literature, the FDA, and WADA say about CJC-1295.